


# FAST Facts

Since 2008, FAST has funded numerous research grants, dedicated scientific labs, biomarker and endpoint measure developments to find meaningful and transformative therapeutics for those living with Angelman syndrome.



## We move fast!

- **2008** **FAST** launches with the mission to cure AS
- **2012** **FAST** funds human clinical trial on minocycline for the treatment of AS
- **2013** **FAST** launches the FIRE (FAST Integrative Research Environment) initiative to identify and characterize treatments for AS through a collaborative research consortium
- **2014** **FAST** funds the creation of 2 novel animal models of AS
- **2015** **FAST** launches the first medical research grade global AS registry to prepare for clinical trials
- **2016** **FAST** FAST receives the largest grant to AS given to date of \$5.8 million for a 24 month translational research initiative
- **2017** **FAST** launches the for-profit GeneTx Biotherapeutics to develop an antisense oligonucleotide (ASO) program for AS
- **2020** **FAST** establishes an infrastructure with a dedicated UC Davis Laboratory
- **2020** **FAST** funded GeneTx launches Phase 1/2 Clinical Trial
- **2021** **FAST** invests \$1M into ABOM
- **2021** **FAST** launches INSYNC-AS (International Angelman Syndrome Research Council)